Neuroleptic malignant syndrome associated with atypical antipsychotic drugs

CNS Drugs

Volumn 23, Issue 6, 2009, Pages 477-492

  Trollor, Julian N ^a,b   Chen, Xiaohua ^a,b   Sachdev, Perminder S ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; CLINICAL EXAMINATION; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DEPRESSIVE PSYCHOSIS; DIAPHORESIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG MECHANISM; DRUG UTILIZATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPONATREMIA; LEUKOCYTOSIS; LEUKOPENIA; LIVER FUNCTION TEST; MONOTHERAPY; MOOD DISORDER; MUSCLE RIGIDITY; MUSCLE STIFFNESS; MYOGLOBINURIA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SYMPTOM; TACHYCARDIA; TREMOR;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 66749158086     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923060-00003     Document Type: Review

References (130)

1. Delay J, Pichot P, Lemperiere T, et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris) 1960 Jan; 118 (1): 145-52
2. Berardi D, Amore M, Keck Jr PE, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998 Oct 15; 44 (8): 748-54
3. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: and analysis of 115 cases. Biol Psychiatry 1987 Aug; 22 (8): 1004-20
4. Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand 1994 Dec; 90 (6): 424-6
5. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry 1990 Sep; 147 (9): 1149-55
6. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986 Apr; 73 (4): 337-47
7. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997 Aug; 154 (8): 1156-8
8. Adityanjee Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999 May-Jun; 22 (3): 151-8
9. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989 Jan; 50 (1): 18-25
10. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005 Jul-Aug; 28 (4): 197-204
11. Levinson DF, Simpson G. Sequelae of neuroleptic malignant syndrome. Biol Psychiatry 1987 Feb; 22 (2): 237-8
12. Spirko BA, Wiley II JF. Serotonin syndrome: a new pediatric intoxication. Pediatr Emerg Care 1999 Dec; 15 (6): 440-3
13. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22 (3): 475-83
14. Weller M, Kornhuber J. Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report. Aust N Z J Med 1996 Apr; 26 (2): 232-3
15. Nemecek D, Rastogi-Cruz D, Csernansky JG. Atropinism may precipitate neuroleptic malignant syndrome during treatment with clozapine [published erratum appears in Am J Psychiatry 1993 Dec; 150 (12): 1910]. Am J Psychiatry 1993 Oct; 150 (10): 1561.
16. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988 Dec 24-31; 2 (8626-8627): 1500
17. Tsai G, Crisostomo G, Rosenblatt ML, et al. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995 Jun; 7 (2): 91-5
18. DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991 Mar; 52 (3): 105-7
19. Sachdev P, Kruk J, Kneebone M, et al. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995 Oct; 15 (5): 365-71
20. Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990; 2 (4): 251-3
21. Goates MG, Escobar JI. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge. J Clin Psychopharmacol 1992 Apr; 12 (2): 139-40
22. Viner MW, Escobar JI. An apparent neurotoxicity associated with clozapine. J Clin Psychiatry 1994 Jan; 55 (1): 38-9
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
24. Pope Jr HG, Keck Jr PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986 Oct; 143 (10): 1227-33
25. Caroff SN, Mann SC, Lazarus A, et al. Neuroleptic malignant syndrome: diagnostic issues. Psychiatr Ann 1991; 21: 130-47
26. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985 Oct; 142 (10): 1137-45
27. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986 Dec; 143 (12): 1587-90
28. Adityanjee. The spectrum concept and prevalence of neuroleptic malignant syndrome. Am J Psychiatry 1988 Aug; 145 (8): 1041
29. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992 Feb; 53 (2): 56-62
30. Adityanjee, Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neurolpetic malignant syndrome. Int J Neuropsychopharmacol 1999; 2: 129-44
31. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994 Mar; 182 (3): 168-73
32. Duggal HS. Possible neuroleptic malignant syndrome associated with paliperidone. J Neuropsychiatry Clin Neu-rosci 2007; 19 (4): 477-8
33. Jaan MW, Grimsley SR, Gray EC, et al. Pharamaco-kinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24 (2): 161-76
34. Pope Jr HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986 Aug; 174 (8): 493-5
35. Blum A, Mauruschat W. Temperaturanstiege und Blutei- weißveränderungen unter der Therapie mit Neuroleptika-unter besonderer berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin. Pharmakopsychia-trie 1972; 5: 155-69
36. Nitenson NC, Kando JC, Frankenburg FR, et al. Fever associated with clozapine administration. Am J Psychiatry 1995 Jul; 152 (7): 1102
37. Thornberg SA, Ereshefsky L. Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharma-cotherapy 1993 Sep-Oct; 13 (5): 510-4
38. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992; 63 (1): 51-70
39. Caroff SN, Mann SC, Campbell EC. Atypical anti-psychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000; 30 (5): 314-21
40. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003 Jan; 2 (1): 21-35
41. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004 Apr; 65 (4): 464-70
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
43. Ferioli V, Manes A, Melloni C, et al. Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief treatment with dantrolene. Can J Psychiatry 2004 Jul; 49 (7): 497-8
44. Corallo CE, Ernest D. Atypical neuroleptic malignant syndrome with long-term clozapine. Crit Care Resusc 2007 Dec; 9 (4): 338-40
45. Skarpathiotakis M, Westreich N. NMS after clozapine initiation. J Am Acad Child Adolesc Psychiatry 2005 Nov; 44 (11): 1101-2
46. Gambassi G, Capurso S, Tarsitani P, et al. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res 2006 Jun; 18 (3): 266-70
47. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry 1998 Dec; 32 (6): 884-6
48. Filice GA, McDougall BC, Ercan-Fang N, et al. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother 1998 Nov; 32 (11): 1158-9
49. Hanel RA, Sandmann MC, Kranich M, et al. Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine. Arq Neuropsiquiatr 1998 Dec; 56 (4): 833-7
50. Moltz DA, Coeytaux RR. Case report: possible neuroleptic malignant syndrome associated with olanzapine. J Clin Psychopharmacol 1998 Dec; 18 (6): 485-6
51. Emborg C. Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskr Laeger 1999 Mar 8; 161 (10): 1424-5
52. Mujica R, Weiden P. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. Am J Psychiatry 2001 Apr; 158 (4): 650-1
53. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome: a case. Hum Psychopharmacol 2003 Jun; 18 (4): 301-9
54. Hall RCW, Appleby B, Hall RCW. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005 Jan; 98 (1): 114-7
55. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatrica Scandinavica 2005 Sep; 112 (3): 238-40, discussion 40
56. Reeves RR, Torres RA, Liberto V, et al. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 2002 May; 22 (5): 641-4
57. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2002 Jun; 26 (5): 897-902
58. Stevens DL, Lee MR, Padua Y. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy. Pharmacotherapy 2008 Mar; 28 (3): 403-5
59. Warwick TC, Moningi V, Jami P, et al. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine. Nat Clin Pract Neurol 2008 Mar; 4 (3): 170-4
60. Mishra B, Mishra B, Sahoo S, et al. Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine. Indian J Med Sci 2007 Oct; 61 (10): 570-3
61. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994 Oct 29; 344 (8931): 1228-9
62. Bajjoka I, Patel T, O'Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med 1997 Nov; 30 (5): 698-700
63. Bonwick RJ, Hopwood MJ, Morris PL. Neuroleptic malignant syndrome and risperidone: a case report. Aust N Z J Psychiatry 1996 Jun; 30 (3): 419-21
64. Dave M. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 1995 Aug; 152 (8): 1233-4
65. Gleason PP, Conigliaro RL. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy 1997 May-Jun; 17 (3): 617-21
66. Raitasuo V, Vataja R, Elomaa E. Risperidone-induced neuroleptic malignant syndrome in young patient. Lancet 1994 Dec 17; 344 (8938): 1705
67. Kern JL, Cernek PK. Delayed risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996 Mar; 30 (3): 300
68. Lee MS, Lee HJ, Kim L. A case of delayed NMS induced by risperidone. Psychiatr Serv 2000 Feb; 51 (2): 254-5
69. Levin GM, Lazowick AL, Powell HS. Neuroleptic malignant syndrome with risperidone. J Clin Psychopharmacol 1996 Apr; 16 (2): 192-3
70. Murray S, Haller E. Risperidone and NMS? Psychiatr Serv 1995 Sep; 46 (9): 951
71. Najara JE, Enikeev ID. Risperidone and neuroleptic malignant syndrome: a case report. J Clin Psychiatry 1995 Nov; 56 (11): 534-5
72. Newman M, Adityanjee, Jampala C. Atypical neuroleptic malignant syndrome associated with risperidone treatment. Am J Psychiatry 1997 Oct; 154 (10): 1475
73. Robb AS, Chang W, Lee HK, et al. Case study: risperidone-induced neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol 2000; 10 (4): 327-30
74. Sechi G, Agnetti V, Masuri R, et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol. Biol Psychiatry 2000 Aug; 24 (6): 1043-51
75. Sharma R, Trappler B, Ng YK, et al. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996 Jul-Aug; 30 (7-8): 775-8
76. Singer S, Richards C, Boland RJ. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 1995 Aug; 152 (8): 1234
77. Swanson Jr CL, Price WA, McEvoy JP. Effects of concomitant risperidone and lithium treatment. Am J Psychiatry 1995 Jul; 152 (7): 1096
78. Tarsy D. Risperidone and neuroleptic malignant syndrome. JAMA 1996 Feb 14; 275 (6): 446
79. Meterissian GB. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 1996 Feb; 41 (1): 52-4
80. Zalsman G, Lewis R, Konas S, et al. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 2004 Apr-Jun; 16 (2): 179-82
81. Vercammen L, Buyse GM, Proost JEF, et al. Neuroleptic malignant syndrome in juvenile neuronal ceroid lipo-fuscinosis associated with low-dose risperidone therapy. J Inherit Metab Dis 2003; 26 (6): 611-2
82. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997 Feb 19; 321 (1): 105-11
83. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999 Jun; 20 (6): 612-27
84. Ali S, Pearlman RL, Upadhyay A, et al. Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Clin Psychopharmacol 2006 Aug; 26 (4): 434-6
85. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004 Nov; 19 (6): 351-3
86. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 2005 Feb; 162 (2): 397-8
87. Hammerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole. J Am Acad Child Adolesc Psychiatry 2006 Jun; 45 (6): 639-41
88. Kang S-G, Lee H-J, Lee M-S, et al. Atypical neuroleptic malignant syndrome associated with aripiprazole. J Clin Psychopharmacol 2006 Oct; 26 (5): 534
89. Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pedia-tric patient. Clin Neuropharmacol 2007 Jan-Feb; 30 (1): 47-51
90. Rodriguez OP, Dowell MS. A case report of neuroleptic malignant syndrome without fever in a patient given ari-piprazole. J Okla State Med Assoc 2006 Jul-Aug; 99 (7): 435-8
91. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 2004 Dec; 43 (12): 1457-8
92. Srephichit S, Sanchez R, Bourgeois JA. Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naive patient. J Clin Psychopharmacol 2006 Feb; 26 (1): 94-5
93. Brunelle J, Guigueno S, Gouin P, et al. Aripiprazole and neuroleptic malignant syndrome. JClin Psychopharmacol 2007 Apr; 27 (2): 212-4
94. Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report 2. Prim Care Companion J Clin Psychiatry 2007; 9 (2): 148-9
95. Fischman AJ, Bonab AA, Babich JW, et al. Positron emission tomographic analysis of central 5-hydroxy-tryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996 Nov; 279 (2): 939-47
96. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995 Oct; 275 (1): 101-13
97. Schmidt AW, Lebel LA, Howard Jr HR, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001 Aug 17; 425 (3): 197-201
98. Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone. J Clin Psychopharmacol 2002 Dec; 22 (6): 624-6
99. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother 2006 Jan; 40 (1): 139-42
100. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmacol 2004 Apr; 19 (3): 205-7
101. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004 Jul; 26 (7): 1105-8
102. Ozen ME, Yumru M, Savas HA, et al. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007; 8 (1): 42-4
103. Pandya M, Pozuelo L. A malignant neuroleptic spectrum: of diagnostic criteria and treatment implications in three case reports. Int J Psychiatry Med 2004; 34 (3): 277-85
104. Strawn JR. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res 2006 Jul; 85 (1-3): 298-9
105. Yang SH, McNeely MJ. Rhabdomyolysis pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002 Aug; 159 (8): 1435
106. Vito J, Jummani R, Coffey B. Advanced pediatric psychopharmacology. J Child Adolesc Psychopharmacol 2006 Aug; 16 (4): 498-502
107. Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001; 61 (14): 2123-50
108. Atbasoglu EC, Ozguven HD, Can Saka M, et al. Rhab-domyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry 2004 Dec; 65 (12): 1724-5
109. Peritogiannis V, Tsouli S, Pappas D, et al. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol 2007 Jul-Aug; 30 (4): 245-6
110. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004 Mar; 37 Suppl. 1: S54-64
111. Gallarda T, Olie JP. Neuroleptic malignant syndrome in a 72-year-old man with Alzheimer's disease: a case report and of the literature. Neuropsychopharmacology 2000; 10 Suppl. 3: S357
112. Abay E, Kose R. Amisulpride-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci 2007; 19 (4): 488-9
113. Whalley N, Diaz PL, Howard J. Neuroleptic malignant syndrome associated with the use of quetiapine. Can J Hosp Pharmacy 1999; 52: 112
114. al-Waneen R. Neuroleptic malignant syndrome associated with quetiapine. Can J Psychiatry 2000 Oct; 45 (8): 764-5
115. Bora E, Saffet Gonul A, Akdeniz F, et al. Neuroleptic malignant-like syndrome induced with low-dose quetia-pine treated with electroconvulsive therapy. Eur Psychiatry 2003 Oct; 18 (6): 323
116. Bourgeois JA, Babine S, Meyerovich M, et al. A case of neuroleptic malignant syndrome with quetiapine. J Neuropsychiatry Clin Neurosci 2002; 14 (1): 87
117. Chungh D-S, Kim B-N, Cho S-C. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005 Jul; 19 (4): 422-5
118. Grignon S, Brethes JI, Chamberland M, et al. Incipient neuroleptic malignant syndrome with quetiapine/ paroxetine combination treatment: atypical presentation and early, successful rechallenge with olanzapine. Int J Psychiatry Clin Pract 2005; 9 (4): 296-8
119. Sing KJ, Ramaekers GMGI, Van Harten PN. Neuroleptic malignant syndrome and quetiapine [published erratum appears in Am J Psychiatry 2002 May; 159 (5): 892]. Am J Psychiatry 2002 Jan; 159 (1): 149-50
120. Solomons K. Quetiapine and neuroleptic malignant syndrome. Can J Psychiatry 2002 Oct; 47 (8): 791
121. Stanley AK, Hunter J. Possible neuroleptic malignant syndrome with quetiapine. Br J Psychiatry 2000 May; 176: 497
122. Sugden SG, Bourgeois JA, Kile SJ, et al. Neuroleptic malignant syndrome with dermatologic complications. J Clin Psychopharmacol 2004 Dec; 24 (6): 676-8
123. Hatch CD, Lund BC, Perry PJ. Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics. Pharmacotherapy 2001 Aug; 21 (8): 1003-6
124. Matsumoto R, Kitabayashi Y, Nakatomi Y, et al. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 2005 Apr; 162 (4): 812
125. Precourt A, Dunewicz M, Gregoire G, et al. Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Ann Pharmacother 2005 Jan; 39 (1): 153-6
126. Kobayashi A, Kawanishi C, Matsumura T, et al. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report. Prog Neuro-psychopharmacol Biol Psychiatry 2006 Aug 30; 30 (6): 1170-2
127. Suzuki K, Awata S, Nakagawa K, et al. Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy. Mov Disord 2006 Jan; 21 (1): 123-4
128. Coward DM, Imperato A, Urwyler S, et al. Biochemical and behavioural properties of clozapine. Psychopharma-cology 1989; 99 Suppl.: S6-12
129. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993 Jan; 77 (1): 185-202
130. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005 Jun 30; 135 (3): 249-56